Standout Papers

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib... 2018 2026 2020 2023 379
  1. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients (2018)
    Zhe Yang, Nong Yang et al. Clinical Cancer Research

Immediate Impact

1 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

The hallmarks of cancer immune evasion
2024 Standout
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
2 intermediate papers

Works of Zhe Yang being referenced

<p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p>
2020
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
2018 Standout

Author Peers

Author Last Decade Papers Cites
Zhe Yang 335 475 395 44 830
Daliu Min 480 317 325 48 965
Takafumi Okabe 449 463 476 29 932
Zhaolin Xu 387 302 257 39 859
Gregory H. Ripple 268 323 510 22 954
Yutaka Yasunaga 243 377 249 30 818
Yasuhito Fujisaka 244 270 474 50 871
Christudas Morais 476 305 143 59 986
Yilun Chen 365 253 325 48 913
Shuang Liu 402 261 204 33 709
Rhoda Arzoomanian 504 148 312 27 934

All Works

Loading papers...

Rankless by CCL
2026